

Meeting Minutes: Drug Formulary Committee - DRAFT

Date & Time: October 1, 2020; 5:15-9:00 PM
Minutes prepared by: Justin Johnson and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- Members in attendance: Stuart Williams, J.D.; Margaret Artz, RPh., PhD.; Mary Mescher Benbenek, APRN, PhD.; Monica Brands, RPh.; Al Heaton, PharmD.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; James Phillips, MD.; Ramona Powell, PharmD.; Kelly Ruby, PharmD.; Michael Sprehe, MD.;
- Members absent: None
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.;
- Others in attendance: Ariane Casey, PharmD.; Justin Johnson, PharmD.

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- Minutes from the August 2020 meetings were reviewed and accepted as presented.

DHS Housekeeping - None

Old Business – None

New Business

Existing Specialty Drugs for Continued PA

- The committee discussed Hepatitis C and recommended to the department by a unanimous vote that Hepatitis C remain on PA with the proposed changes to the existing criteria.

Preferred Drug List Review

- The committee discussed the Hepatitis C Agents therapeutic class and recommended the following to the department by a unanimous vote:

- HARVONI PELLETT (ORAL) and SOVALDI PELLETT (ORAL) to be added to the PDL as nonpreferred
 - DAKLINZA (ORAL), OLYSIO (ORAL), TECHNIVIE (ORAL), and VIEKIRA XR (ORAL) to be removed from the PDL
 - Change “HARVONI (ORAL)” and “SOVALDI (ORAL)” to “HARVONI TABLET (ORAL)” and “SOVALDI TABLET (ORAL)” to distinguish the tablet formulation from the pellet formulation
- The committee discussed the HIV/AIDS therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred HIV/AIDS drugs be added to the PDL as presented.
 - The committee discussed the Hemophilia Treatments therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hemophilia Treatment drugs be added to the PDL as presented. One DFC member, Dr. Michael Sprehe, recused himself from the discussion and abstained from voting for this class.
 - The committee discussed the Hypoglycemics, Alpha-Glucosidase Inhibitors therapeutic class and recommended to the department by a unanimous vote for GLYSET (ORAL) to be changed from preferred to nonpreferred.
 - The committee discussed the Hypoglycemics, Incretin Mimetics therapeutic class and recommended to the department by a unanimous vote for RYBELSUS (ORAL) and TRIJARDY XR (ORAL) to be added to the PDL as nonpreferred.
 - The committee discussed the Hypoglycemics, Insulin and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - HUMALOG CARTRIDGE (SUBCUTANE.), HUMALOG JUNIOR KWIKPEN (SUBCUTANE.), HUMALOG PEN (SUBCUTANE.), HUMALOG MIX PEN (SUBCUTANE.), HUMULIN 500 U/M PEN (SUBCUTANE.), INSULIN LISPRO PEN (SUBCUTANE.) and INSULIN LISPRO VIAL (SUBCUTANE.) to be changed from nonpreferred to preferred.
 - INSULIN ASPART VIAL, INSULIN ASPART FLEXPEN, INSULIN ASPART PENFILL, INSULIN ASPART/INSULIN ASPART PROTAMINE VIAL (AG) (SUBCUTANEOUS), INSULIN ASPART/INSULIN ASPART PROTAMINE INSULIN PEN (AG) (SUBCUTANEOUS), INSULIN LISPRO JUNIOR KWIKPEN, INSULIN LISPRO PROTAMINE MIX KWIKPEN (AG) (SUBCUTANEOUS), LYUMJEV VIAL, LYUMJEV KWIKPEN U-100, LYUMJEV KWIKPEN U-200, NOVOLIN PEN OTC (SUBCUTANE.), SEMGLEE VIAL, SEMGLEE PEN, and TRESIBA VIAL to be added to the PDL as nonpreferred.
 - The committee discussed the Hypoglycemics, SGLT2 therapeutic class and recommended to the department by a majority vote that the preferred and non-preferred Hypoglycemics, SGLT2 drugs remain as presented.
 - The committee discussed the Hypoglycemics, Sulfonylureas therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hypoglycemics, Sulfonylurea drugs remain as presented.

- The committee discussed the Hypoglycemics, TZD therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hypoglycemics, TZD drugs remain as presented.
- The committee discussed the Immunomodulators, Atopic Dermatitis therapeutic class and recommended to the department by a unanimous vote for ELIDEL (TOPICAL) to be changed from preferred to nonpreferred.
- The committee discussed the Immunosuppressives, Oral therapeutic class and recommended the following to the department by a unanimous vote:
 - CELLCEPT SUSPENSION (ORAL) to be changed from nonpreferred to preferred
 - EVEROLIMUS TABLET (ZORTRESS) (ORAL) to be added to the PDL as nonpreferred
- The committee discussed the Lipotropics, Other therapeutic class and recommended the following to the department by a unanimous vote:
 - JUXTAPID (ORAL) and LOFIBRA TABLET (ORAL) to be removed from the PDL
 - NEXLETOL (ORAL) and NEXLIZET (ORAL) to be added to the PDL as nonpreferred
- The committee discussed the Lipotropics, Statins therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Lipotropics, Statin drugs remain as presented.
- The committee discussed the Multiple Sclerosis Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - BAFIERTAM (ORAL), DALFAMPRIDINE ER (ORAL), DIMETHYL FUMARATE (ORAL), KESIMPTA PEN (SUBCUTANE.), LEMTRADA (INTRAVEN.), OCREVUS (INTRAVEN.), TYSABRI (INTRAVEN.), VUMERITY (ORAL), and ZEPOSIA (ORAL) be added to the PDL as nonpreferred
- The committee discussed the Neuropathic Pain therapeutic class and recommended the following to the department by a unanimous vote:
 - LIDOPURE PATCH (TOPICAL) to be removed from the PDL
 - ZTLIDO (TOPICAL) to be added to the PDL as nonpreferred
- The committee discussed the NSAIDs therapeutic class and recommended the following to the department by a unanimous vote:
 - DICLOFENAC GEL to be removed from the PDL
 - FLECTOR (TOPICAL) to be changed from nonpreferred to preferred
 - ARTHROTEC (ORAL), DICLOFENAC PATCH (AG) (TRANSDERMAL), and DICLOFENAC SODIUM/MISOPROSTOL (ORAL) to be added to the PDL as nonpreferred
 - Change “DICLOFENAC SOCIUM (ORAL)” to “DICLOFENAC SODIUM (ORAL)”
- The committee discussed the Ophthalmic Antibiotics therapeutic class and recommended the following to the department by a unanimous vote:
 - MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC) to be changed from nonpreferred to preferred
 - VIGAMOX (OPHTHALMIC) to be changed from preferred to nonpreferred

- The committee discussed the Ophthalmics for Allergic Conjunctivitis therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Ophthalmics for Allergic Conjunctivitis drugs remain as presented.
- The committee discussed the Ophthalmics, Anti-Inflammatories therapeutic class and recommended to the department by a unanimous vote for FLUOROMETHOLONE (OPHTHALMIC) and PREDNISOLONE ACETATE (OPHTHALMIC) be added to the PDL as preferred.
- The committee discussed the Ophthalmics, Glaucoma Agents therapeutic class and recommended to the department by a unanimous vote for XELPROS (OPHTHALMIC) to be added to the PDL as nonpreferred.
- The committee discussed the Opiate Dependence Treatments therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Opiate Dependence Treatment drugs remain as presented.
- The committee discussed the Otic Antibiotics therapeutic class and recommended to the department by a unanimous vote for CIPROFLOXACIN/FLUOCINOLONE (AG) (OTIC) to be added to the PDL as nonpreferred.
- The committee discussed the PAH Agents, Oral and Inhaled therapeutic class and recommended the following to the department by a unanimous vote:
 - AMBRISENTAN (ORAL) and REVATIO SUSPENSION (ORAL) to be changed from nonpreferred to preferred
 - LETAIRIS (ORAL) to be changed from preferred to nonpreferred
 - SILDENAFIL SUSPENSION (ORAL) and SILDENAFIL SUSPENSION (AG) (ORAL) to be added to the PDL as nonpreferred
 - Change “SILDENAFIL (ORAL)” to “SILDENAFIL TABLET (ORAL)” to clarify which formulation is preferred
- The committee discussed the Pancreatic Enzymes therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Pancreatic Enzyme drugs remain as presented.
- The committee discussed the Phosphate Binders therapeutic class and recommended the following to the department by a unanimous vote:
 - SEVELAMER CARBONATE TABLET (ORAL) to be changed from nonpreferred to preferred
 - RENAGEL (ORAL) to be changed from preferred to nonpreferred
- The committee discussed the Platelet Aggregation Inhibitors therapeutic class and recommended the following to the department by a unanimous vote:
 - AGGRENOX (ORAL) to be removed from the PDL
 - BRILINTA (ORAL) and PRASUGREL (ORAL) to be changed from nonpreferred to preferred
 - DURLAZA (ORAL) and YOSPRALA (ORAL) to be removed from the PDL

- The committee discussed the Progestins for Cachexia therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Progestins for Cachexia drugs remain as presented.
- The committee discussed the Proton Pump Inhibitors therapeutic class and recommended the following to the department by a unanimous vote:
 - ESOMEPRAZOLE CAPSULES (ORAL) and LANSOPRAZOLE CAPSULES (ORAL) to be changed from nonpreferred to preferred
 - ESOMEPRAZOLE SUSPENSION (ORAL) and ZEGERID (ORAL) to be added to the PDL as nonpreferred
- The committee discussed the Sedative Hypnotics therapeutic class and recommended to the department by a unanimous vote for DAYVIGO (ORAL) to be added to the PDL as nonpreferred.
- The committee discussed the Sickle Cell Treatments therapeutic class and recommended to the department by a unanimous vote for OXBRYTA (ORAL) to be changed from nonpreferred to preferred.
- The committee discussed the Smoking Cessation therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Smoking Cessation drugs remain as presented.
- The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
 - ADDERALL XR (ORAL), CONCERTA (ORAL), METHYLIN SOLUTION (ORAL), and METHYLPHENIDATE SOLUTION (ORAL) to be changed from nonpreferred to preferred
 - AMPHETAMINE SALT COMBO ER (ORAL), METHYLPHENIDATE CD (ORAL), METHYLPHENIDATE CHEWABLE TABLETS (ORAL), METHYLPHENIDATE ER (CONCERTA) (ORAL) and METHYLPHENIDATE ER 72 MG TABLETS (ORAL) to be changed from preferred to nonpreferred
 - AMPHETAMINE SUSPENSION ER (ORAL), METHYLPHENIDATE ER (APTENSIO XR) (AG) (ORAL), and METHYLPHENIDATE SOLUTION (AG) (ORAL) to be added to the PDL as nonpreferred
 - ARMODAFINIL (ORAL), METHYLIN CHEWABLE TABLETS (ORAL), and DEXEDRINE TABLET (ORAL) to be removed from the PDL
- The committee discussed the Ulcerative Colitis therapeutic class and recommended the following to the department by a unanimous vote:
 - MESALAMINE (LIALDA) (ORAL), MESALAMINE (ROWASA) (RECTAL), MESALAMINE (SFROWASA) (RECTAL), and MESALAMINE ER (APRISO) (ORAL) to be added to the PDL as nonpreferred.

Adjournment

- The meeting was adjourned at approximately 9:20 PM Central Time.